文献速递骨软组织肉瘤与黑色素瘤

局部高危软组织肉瘤新辅助化疗联合或不联合区域热疗的免疫浸润:EORTC 62961-ESHO 95 转化研究

Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.
PubMed 文献 · Eur J Cancer · 2021-10-16

基于EORTC 62961-ESHO 95随机试验的转化研究,对109例高危软组织肉瘤患者(新辅助化疗53例,联合区域热疗56例)的137份序贯活检进行评估。结果显示治疗后TILs增高、FOXP3调节性T细胞下降、PD-L1表达转为不可测;治疗后高TILs与LPFS和DFS改善相关,高CD8浸润与LPFS和DFS改善相关。结论认为术前治疗可将基线非炎症肿瘤转为炎症肿瘤,联合区域热疗可启动肿瘤微环境增强抗肿瘤免疫活性。

要点

  • 治疗后高TILs与LPFS(HR 0.34)和DFS(HR 0.38)改善独立相关。
  • 高CD8细胞浸润与LPFS(HR 0.27)和DFS(HR 0.25)改善相关。
  • 联合区域热疗组10年生存改善与治疗后免疫浸润相关。

核心结论

  • 术前治疗可将基线非炎症肿瘤转化为炎症肿瘤,治疗后免疫浸润可预测临床结局。
  • 联合区域热疗可启动肿瘤微环境,增强高危软组织肉瘤的抗肿瘤免疫活性。

研究设计与样本

  • EORTC 62961-ESHO 95随机临床试验的转化研究项目。
  • 纳入1997年7月至2006年11月随机分组的109例患者,新辅助化疗53例,新辅助化疗联合区域热疗56例。
  • 共获取137份活检,评估TILs及CD8、FOXP3、PD-1、PD-L1,为四周期治疗后序贯活检。

主要发现

  • 配对第二次活检中TILs增高,不依赖治疗分组(p < 0.001)。
  • FOXP3调节性T细胞下降(p = 0.002),肿瘤PD-L1表达转为不可测。
  • 多因素分析中,治疗后高TILs与LPFS相关(HR: 0.34; 95% CI 0.15-0.75; p = 0.008),与DFS相关(HR: 0.38; 95% CI 0.17-0.82; p = 0.015)。
  • 比较两组治疗后免疫浸润时,肿瘤缓解与新辅助化疗联合区域热疗相关(p = 0.013),与高TILs相关(p = 0.064)。
  • 高CD8细胞浸润与LPFS改善相关(HR: 0.27; 95% CI 0.09-0.79; Log-rank p = 0.011),与DFS改善相关(HR: 0.25; 95% CI 0.09-0.73; Log-rank p = 0.006)。

临床怎么用

  • 治疗后TILs和CD8浸润可作为高危软组织肉瘤新辅助治疗后的预后评估指标。
  • 区域热疗联合新辅助化疗可能通过改善肿瘤免疫微环境增强抗肿瘤免疫,支持其免疫调节作用。

局限性

  • 免疫浸润分析基于109例患者的亚组,样本量有限。
  • PD-1相关结果未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EORTC 62961-ESHO 95 randomised trial showed improved long-term survival of patients with high-risk soft-tissue sarcoma by adding regional hyperthermia to neoadjuvant chemotherapy. We hypothesised that immune infiltrate of patients treated with neoadjuvant therapy associate with clinical outcome. METHODS: Tumour infiltrating lymphocytes (TILs) and CD8, FOXP3, PD-1, and PD-L1 were evaluated in sequential biopsies of patients after four cycles of therapy. RESULTS: From a subgroup of 109 patients who had been randomised between July 1997 and November 2006 to neoadjuvant chemotherapy (53 patients) or neoadjuvant chemotherapy with regional hyperthermia (56 patients), 137 biopsies were obtained. TILs increased in paired second biopsies independent of treatment allocation (p < 0.001). FOXP3 regulatory T cells decreased (p = 0.002), and PD-L1 expression of tumours became undetectable. In the multivariate analysis, post-treatment high TILs correlated to LPFS (HR: 0.34; 95% CI 0.15-0.75; p = 0.008) and DFS (HR: 0.38; 95% CI 0.17-0.82; p = 0.015). In comparing post-treatment immune infiltrate between treatment arms, tumour response was associated with neoadjuvant chemotherapy with regional hyperthermia (p = 0.013) and high TILs (p = 0.064). High CD8 cell infiltration was associated with improved LPFS (HR: 0.27; 95% CI 0.09-0.79; Log-rank p = 0.011) and DFS (HR: 0.25; 95% CI 0.09-0.73; Log-rank p = 0.006). Improved survival at 10 years was associated with immune infiltrate after neoadjuvant chemotherapy with regional hyperthermia. CONCLUSION: Preoperative therapy re-programs a non-inflamed tumour at baseline into an inflamed tumour. The post-treatment immune infiltrate became predictive for clinical outcomes. The combination with regional hyperthermia primes the tumour microenvironment, enabling enhanced anti-tumour immune activity in high-risk soft tissue sarcomas. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00003052.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Issels RD, Noessner E, Lindner LH, et al. Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. Eur J Cancer. 2021. PMID: 34666214. doi:10.1016/j.ejca.2021.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。